Talyta Ellen de Jesus Dos Santos
Overview
Explore the profile of Talyta Ellen de Jesus Dos Santos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moura A, Duarte F, Barbosa M, Santos T, Goncalves Lemes R
Clinics (Sao Paulo)
. 2019 Sep;
74:e771.
PMID: 31508719
Objectives: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological...
2.
Duarte F, Santos T, Barbosa M, Moura A, DE Vasconcelos J, Rocha-Filho F, et al.
In Vivo
. 2018 Dec;
33(1):277-280.
PMID: 30587636
Background/aim: Although risk stratification using the Prognostic Scores Systems (IPSS, WPSS and IPSS-R) incorporate key information about prognosis of patients with Myelodysplastic syndromes (MDS), patients classified as low-risk may evolve...
3.
Leitao J, Goncalves Lemes R, Barbosa M, Araujo B, Barroso K, Kaufman J, et al.
Rev Assoc Med Bras (1992)
. 2018 Dec;
64(10):882-884.
PMID: 30517233
Wernick's Encephalopathy (WE) is an acute neuropsychiatric syndrome caused by thiamine deficiency post hematopoietic stem cell transplant (HSCT). WE is associated with high mortality and morbidity rates, but due to...
4.
Duarte F, Goncalves Lemes R, Santos T, Barbosa M, DE Vasconcelos J, Rocha-Filho F, et al.
J Med Case Rep
. 2017 May;
11(1):143.
PMID: 28527473
Background: Myelodysplastic syndromes are heterogeneous disorders. Patients with myelodysplastic syndrome disease often have ineffective hematopoiesis, cytopenias, blood cell dysplasia in one or more cell types, and are at high risk...
5.
Nogueira Dos Santos T, Duarte F, Filho P, Santos T, Barbosa M, Filho T, et al.
Rev Assoc Med Bras (1992)
. 2016 Dec;
62 Suppl 1:39-43.
PMID: 27982318
The aim of the study was to investigate the association between oxidative stress and DNA damage with grafting time in patients submitted to autologous hematopoietic stem-cell transplantation (HSCT). The study...
6.
Duarte F, Santos T, Barbosa M, Kaufman J, Vasconcelos J, Goncalves Lemes R, et al.
Rev Assoc Med Bras (1992)
. 2016 Dec;
62 Suppl 1:25-28.
PMID: 27982317
The hematopoietic stem cell transplantation (HSCT) is the only curative alternative for Myelodysplastic Syndrome (MDS), but many patients are not eligible for this treatment, as there are several limiting factors,...
7.
Cavalcante J, Goncalves Machado R, Rocha Laurentino M, Santos T, Bandeira I, Filho P, et al.
Hematol Oncol Stem Cell Ther
. 2015 Dec;
9(1):14-9.
PMID: 26686970
Objective/background: Sickle-cell anemia (SCA) is a genetic blood disease characterized by chronic inflammation and a heterogeneous clinical picture. Serum tumor necrosis factor (TNF-alpha) and interleukin 10 (IL-10) levels are associated...
8.
Barbosa M, Santos T, Nogueira Dos Santos T, Pedrosa A, Elias D, Leal L, et al.
Basic Clin Pharmacol Toxicol
. 2015 Sep;
118(4):271-8.
PMID: 26346295
The aim of the study was to investigate the possible anti-inflammatory and antioxidant effects of BAY 73-6691 on neutrophils from SCA patients. This study included 35 patients with a molecular...
9.
Santos T, Goncalves R, Barbosa M, da Silva Jr G, Daher E
Blood Cells Mol Dis
. 2014 Dec;
54(3):297-301.
PMID: 25500149
Background: The aim of this study was to evaluate the monocyte chemoatractant protein-1 (MCP-1) as a novel biomarker of renal lesion in sickle cell disease (SCD) and correlate it with...
10.
Duarte F, Goncalves R, Barbosa M, Filho F, Santos T, Nogueira Dos Santos T, et al.
Rev Bras Hematol Hemoter
. 2014 Jul;
36(3):196-201.
PMID: 25031059
Background: At the time of diagnosis, more than 50% of patients with myelodysplastic syndrome have a normal karyotype and are classified as having a favorable prognosis. However, these patients often...